| VOL. 13 | NO. 7
VIEW LATEST ISSUE
2017 Media KIt
Calendar of Events
Renew Your Subscription
Submit an Article
Research & Development
Business & Government Policy
Products & Services
CANCER RESEARCH NEWS:
CLICK HERE FOR WHAT'S NEW IN:
High Throughput Screening
Guest Commentary: Congress must do its job and support federal research funding
Out of order: A word about communication
Guest Commentary: Planning successful oncology trials amid a rapidly shifting treatment landscape
Bubbles that need some popping
Out of order: (Not a) Goo goo g’job
Guest Commentary: CRISPR--The past, present and future
Convergence: Where art thou?
Guest Commentary: Using EHR data in research--Pragmatic trials are just the beginning
Guest Commentary: Assessing the state of liquid biopsy and its future path
Out of order: Reproduci-bull?
The irreproducibility of published science
Guest Commentary: Validating antibodies--The good, the bad and the necessary
Publishers’ commentary: From an amazing 2016 to a promising 2017
Out of Order: Undaunted
Guest Commentary: Sample-handling automation
The next big thing
Guest Commentary: The Science of cell culture--Maintaining phenotypic and genotypic heterogeneity
Out of order: Being human
Guest Commentary: Accelerating discovery through contract chemical synthesis
Pediatric pharmacology, part 2
Guest Commentary: What if mice could be more like humans?
Immunotherapy Clinical Studies: The Way Forward
Out of order: I am not an animal
Guest commentary: Direct-to-consumer genetic testing--Helpful or harmful?
Moonshot for pediatric pharmacology
Market insight: The changing biopharma risk equation
Out of order: The cost of a free market
Newly published PLOS paper calls for better sharing of genomic data
Thin really does matter after all
Guest Commentary: Back to cancer’s drawing board
Guest Commentary: Individualized medicine vs. precision medicine
Guest Commentary: Data visualization--New directions or just familiar routes?
Out of order: A story about anecdotes
Phenotype beats genotype; measurements beat guessing
Guest Commentary: New frontiers for target ID in oncology--Where will the next generation of targets come from?
Out of order: Clinicians must return to basics
Guest Commentary: Go parallel in a big way
R&D: Risk and delivery in different cultures
Market insight: Prescription medicines--Costs in context
Out of order: Avoiding extremes
A very busy 2016? The intersection of M&As and personalized medicine
Guest Commentary: An ethical imperative to use biosimulation in drug development
Out of order: You treat what you are
Guest commentary: Immunotherapy research takes a lead showcasing innovative cancer models and translational platforms
Reader discretion is advised
Guest Commentary: Defeating lupus starts with a diagnosis
Out of order: When numbers fail
Guest Commentary: Building a problem or a solution?
Of minimum wage and cancer drugs
Guest Commentary: An industrywide call for greater antibody information
Out of Order: Picture this, will you?
Commentary: The changing face of nonclinical development
The Internet of medical things
Commentary: Encouraging advances now underway in cancer research
Out of order: Asilomar remembered
Commentary: Intralesional Melanoma Treatments Are Ready for Prime Time
Djerassi, spring break and mass spectrometry
Commentary: Precision medicine is not just about genetic testing
Commentary: Candy Land, opioid addiction and help that’s on its way
Out of order: The vaccine de-bait
The tyranny of averages
A grad student Q&A with Peter T. Kissinger
Out of Order: Substance over volume
Guest commentary: Solutions to the drug development cycle and antibiotic resistance problems
Publishers' commentary: A decade down and more to come
Working at science, science at work
Guest commentary: Clinical trial data inaccuracies--Challenges for personalized medicine
Out of order: Regulator, go to heal
Success of new-generation metabolo-therapies in personalized medicine depends on measuring bioenergetic health
Peer review and the life sciences
Guest Commentary: Factors impacting genome editing success and failure--A focus on cell lines
Out of Order: The undiscovered country
Patent Docs: FDA releases draft guidances on biosimilars
Commentary: Debunking the myths of treating hepatitis C
Guest Commentary: New trend in regulatory affairs consulting delivers reduced costs and improved processes
Out of Order: Modestly modeled
Commentary: Personalized medicine--Bridging the gaps
Red tape rising
Guest commentary: The clinical trial landscape and its data collection challenges
Commentary: Developing Humanized Cancer Models for Cost-Effective and Productive Cancer Drug Discovery
Out of Order: Mutants Among Us
The future of stem cells faces a Myriad of obstacles
My war on poverty
Commentary: Automation—The answer to tedious manual sample preparation for mass spectrometry?
Out of Order: Human compassion vs. scientific rigor
Commentary: Copy number analysis provides new clinical insights into solid tumor cancers
Commentary: The healthcare exchange you haven’t heard about
Let’s thank the engineers
Commentary: Companion diagnostics--Making drug delivery personal
Where we've been, where we're going
OUT OF ORDER: Taking a global view
Commentary: Federal Circuit enforces written description requirement even for negative limitations and narrower claims
Let’s talk about stagnovation
Customized automation in a highly regulated environment
Cell sorting for everyone: From the core lab to your lab
Out of Order: Having words
A guide for potency assay development of cell-based product candidates
A celebration of instrumentation
Immuno-oncology: The importance of combination therapies
Out of Order: Inspired cynic
Oncology outsourced: An emerging research model
Facts don’t matter … until they do
Finding the right balance
Out of Order: Success-story succession
Publishers announce changes, broader focus for DDNEWS
Hire education: Which came first, the university or the economy?
Your personal genome sequenced: Where do you go from here?
Facing the patent cliff head-on
Out of Order: Attention to detail
Revolutionizing and personalizing global health
Keeping up is hard to do
A genome’s got to know its limitations
Out of Order: Didn’t see that coming
The times, they are a changin’ in the biopharma market
That’s not fair! Or is it?
The need for improved half-life extension technologies
Out of Order: Out of the Mayan pan
I’ve fallen … and I can’t get up!
An alternative view of drug-like properties
Changing dynamics in the pharma and biotech industries
I’m not sure about this, but …
Barcodes in drug discovery: The quiet revolution
Who needs R&D tax credits?
CDx, cancer and collaborations: Take our reader survey
Out of Order: If you build it …
Working together to eradicate cell line misidentification and contamination: New practices and policy
The promise of cell therapies in treating chronic diseases
August is back-to-school month
Meeting the need for large-scale production of stem cells
Out of Order: Good news and good luck
Release of proposed AMP rule creates new issues for life-science industry
Making decisions … and making them work
Out of Order: Patently absurd
Paradigm shift: Rethinking type 2 diabetes as a heterogeneous disease
Completing the picture with regulatory information management
Taking inventory of life-science headcounts
Guest Commentary: So you want to collaborate?
Out of Order: Watch that last step
Pay for delay: Right or wrong?
Stuck between evidence and policy
ddn Cancer Research Portal Exclusive: Adjuvants--The Heroes of Immunotherapy
Examining recent approaches to treating solid tumors
Out of Order: Gift horses
Data management that speeds—rather than impedes—advanced DNA sequencing applications
On biobanking: Deposits and withdrawals
The biorepository: The cornerstone of drug development
Multi-parameter optimization: The delicate balancing act of drug discovery
Taxes, innovation and life science jobs
Guest Commentary: Every drug deserves a second chance
The changing face of regulatory outsourcing
So many innovation strategies …
Guest Commentary: Developing new treatments for antibiotic-resistant bacteria
New tools take time
Guest Commentary: Generating more knowledge from data and more value from studies
Molecular screening tools and personalized healthcare: Determining success early in drug development
Too big to succeed, too entrenched to listen
Guest Commentary: What’s driving the decline in AIDS news coverage?
Using patient-relevant models to enhance cancer drug development
Keep it simple, stupid!
FDA issues draft guidance on development of combinations of investigational drugs
Oversaturation vs. tunnel vision
Similar or not similar: That is the question
Publisher’s note: A look at the ddn’s top five stories of 2010
What is analytical chemistry?
New generation of sequencing technologies can replace quantitative PCR in mainstream R&D
Guest Commentary: Bioproduction goes global
Success is a reliable predictor of failure
Quantitating multiple signaling pathway proteins in preclinical and clinical studies
Guest Commentary: Prioritizing hits based on drug-target residence time
The role of nanoemulsions in vaccines, adjuvants, anti-infectives and dermatological treatments
Where will innovation come from?
Use of custom-cell products: Research off the beaten path
Commentary: The importance of liquid handling quality assurance through the drug discovery process
Preanalytical sample handling protocols can advance personalized medicine and science
What is ‘personalized medicine?’
What drug discoverers should know about interferon and its future
Minimizing the cost effects of false positives in cancer testing
Primer on boards of directors
Efficient R&D process can position a drug candidate for commercial success
Every flower needs a STEM
Guest Commentary: Academic institutions play active role in early-stage drug discovery process
Guest commentary: Bioinformatics research enables better biological information
A disappointing end to a disappointing decade
Drug discovery paradigm could shift with cancer center involvement
Warning: Out of focus and multitasking
Translating between preclinical data and clinical outcomes: The bottleneck is always on the other side
Next-gen antibody approaches to cancer treatment offer improved product profiles, greater commercial success
Sample management: The elephant in the room?
Why study a drug in distilled water when urine is cheaper?
Guest commentary: American pathway to generic biologics approval remains undefined
Fixing the U.S. Food and Drug Administration: More money and power—or more competition?
Beware the gatekeeper of information
How small CROs can survive and thrive in a shaky economy
There is no place for humor in science
Patent Office budget shortfall will have long-term effects
Stem cell controversy continues
A culture of innovation: Change we can believe in
Leadership is sharing the credit
Biotech start-ups a bargain, or toast?
Now what do we do? Challenges abound in life sciences for new graduates and experienced alike
A solid team in the life sciences
DDN takes lead with integrated news
Pharma faces Congressional battles in 2009
Today’s biopharma venture capital challenge: Risk-sharing models versus risk avoidance
De-valued dollar makes U.S. companies buyout targets
Ten points to discuss around the coffee pot
Good for iPods, bad for patients
Third Leg of the stool
Why aren’t you running for president?
Must you collaborate with another scientist?
Can states have their (patent) cake and eat it, too?
Make breaking out of the routine, routine
New pharma powers growing in the East
Relative to what?
The Night Before Defense (or A Visit From St. Linus)
Good night and good luck
Polly want a pharmacy
Purple cows and business 2.0.1
Things to come?
Leaving some slack
Back to basic
Gray days for a b/w world
Growing up quickly
Did Doha kill innovation?
Hunt and peck
Center of (your noun here)
An Inconvenient Moore
Look at me
Off base with off-label?
By any other name
Pharma’s danse macabre
Asking the right questions
Sleeping with the enemy
Innovation by declaration
Niche work, if you can get it
Damned if you don’t
Moving the bottleneck
Principle of proof
Pack it in
Looking for dinosaurs
Talk to the animals
Too hot for comfort?
Reporting news; keeping friends
Message (too well) received
Aphorisms for project management
Fooling some of the people
Survival: The “fittest” or the “best fit”?
The fool with email
Back to see the folks
Open (source) for business
In a class of its own: Pharma is unlike any other industry; pass it on.
PR to die for
Finally able to see the forest
PRINT CURRENT PAGE
SEND THIS PAGE TO A COLLEAGUE
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600 | Fax: 440-331-7563
Submit News Release
Terms & Conditions
© Copyright 2017 Old River Publications LLC. All righs reserved. | Web site managed and designed by